Health Care • Biotechnology: Pharmaceutical Preparations
$33.48 ▼ -0.27
(-0.80%)
MKT CAP: $1.64B • VOL: 1.44M
52W L $17 52W H $51
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$28
MEDIAN
$38
MEAN
$38
HIGH
$46
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE URGN TAPE
URGN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $40.51 | $38.50 | 2025-02-14 | $30.47 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $42.18 | $39.51 | 2025-02-06 | $31.47 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $38.17 | $36.83 | 2025-01-29 | $32.14 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $34.15 | — | 2025-01-17 | $32.81 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $29.46 | $31.81 | 2025-01-09 | $29.80 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $39.84 | $34.82 | 2024-12-18 | $29.13 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $32.48 | $33.81 | 2024-12-04 | $31.14 | -4.3% | 48% | C |